[go: up one dir, main page]

MX2010010799A - Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea. - Google Patents

Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.

Info

Publication number
MX2010010799A
MX2010010799A MX2010010799A MX2010010799A MX2010010799A MX 2010010799 A MX2010010799 A MX 2010010799A MX 2010010799 A MX2010010799 A MX 2010010799A MX 2010010799 A MX2010010799 A MX 2010010799A MX 2010010799 A MX2010010799 A MX 2010010799A
Authority
MX
Mexico
Prior art keywords
bone mass
diagnosing
preventing
methods
treating bone
Prior art date
Application number
MX2010010799A
Other languages
English (en)
Inventor
Gerard Karsenty
Patricia F Ducy
Yuli Xie
Donald Landry
Vijay Yadav
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MX2010010799A publication Critical patent/MX2010010799A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos y agentes terapéuticos para reducir o aumentar los niveles de serotonina sérica en un paciente a fin de aumentar o disminuir la masa ósea, respectivamente. En formas de realización preferidas, el paciente se sabe que padece o tiene riesgo para una enfermedad de masa ósea baja tal como osteoporosis y los agentes son inhibidores de TF1 o antagonistas del receptor de serotonina.
MX2010010799A 2008-03-31 2009-03-30 Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea. MX2010010799A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7259608P 2008-03-31 2008-03-31
US9094008P 2008-08-22 2008-08-22
PCT/US2009/038817 WO2009123978A1 (en) 2008-03-31 2009-03-30 Methods of diagnosing, preventing and treating bone mass diseases

Publications (1)

Publication Number Publication Date
MX2010010799A true MX2010010799A (es) 2011-03-25

Family

ID=41135912

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010799A MX2010010799A (es) 2008-03-31 2009-03-30 Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.

Country Status (13)

Country Link
US (2) US8759364B2 (es)
EP (1) EP2282756A4 (es)
JP (1) JP2011516486A (es)
KR (1) KR20110008066A (es)
CN (1) CN102083454A (es)
AU (1) AU2009231892A1 (es)
BR (1) BRPI0908719A2 (es)
CA (1) CA2719505A1 (es)
EA (1) EA201071146A1 (es)
MX (1) MX2010010799A (es)
NZ (1) NZ588737A (es)
WO (1) WO2009123978A1 (es)
ZA (1) ZA201007005B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2719505A1 (en) * 2008-03-31 2009-10-08 The Trustees Of Columbia University In The City Of New York Methods of diagnosing, preventing and treating bone mass diseases
WO2010062829A1 (en) * 2008-11-28 2010-06-03 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for treating osteoporosis
WO2010065333A1 (en) * 2008-12-01 2010-06-10 Lexicon Pharmaceuticals, Inc. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds for the treatment of osteoporosis
US8815883B2 (en) * 2009-11-02 2014-08-26 The Trustees Of Columbia Unviersity In The City Of New York Compounds and methods for inhibiting serotonin synthesis
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
BR112016030965A2 (pt) * 2014-10-06 2017-08-22 Mayo Found Medical Education & Res Composições de veículo-anticorpo e métodos de fabricação e uso das mesmas
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
WO2018060949A1 (en) 2016-09-30 2018-04-05 Roivant Sciences Gmbh Tryptophan hydroxylase inhibitors for use in the treatment of liver diseases
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531713A2 (fr) * 1981-09-16 1984-02-17 Panmedica Sa Nouvelles compositions a base de 5-hydroxytryptophane, leur procede de preparation et medicaments les contenant
US6096342A (en) * 1997-03-12 2000-08-01 The Procter & Gamble Company Dosage forms of risedronate
US6004765A (en) * 1992-02-27 1999-12-21 Delmas; Pierre Assessment of bone fragility and prediction of osteoporotic fracture risk using a quantitative determination of circulating under-carboxylated osteocalcin
US6162638A (en) * 1996-05-06 2000-12-19 Universite Laval Attenuated strains of leishmania and uses thereof
DE60142079D1 (de) * 2000-11-17 2010-06-17 Banyu Pharma Co Ltd Verfahren zur suche nach komponenten, in dem das guanosintriphosphat- (gtp-) bindungsprotein gekoppeltes rezeptorprotein bg37 verwendet wird
EP2002827A2 (en) * 2001-12-05 2008-12-17 The Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
AU2003273281A1 (en) * 2002-05-31 2003-12-19 The Forsyth Institute Methods for increasing bone density
CN102018715A (zh) * 2002-06-17 2011-04-20 费城健康与教育公司 免疫调节及对涉及血清素家族受体及血脑屏障的细胞过程的作用
CN1211396C (zh) 2002-09-09 2005-07-20 上海市伤骨科研究所 趋骨性雌激素化合物，其制备方法及其应用
EP1636167A2 (en) * 2003-06-10 2006-03-22 SmithKline Beecham Corporation 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors
WO2005026129A1 (en) * 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP4805909B2 (ja) * 2004-03-03 2011-11-02 スミスクライン ビーチャム コーポレーション 選択的アンドロゲン受容体モジュレーターとしてのアニリン誘導体
EP1761270A1 (en) * 2004-06-23 2007-03-14 Merck & Co., Inc. Estrogen receptor modulators
US20090137601A1 (en) * 2005-11-23 2009-05-28 Astrazeneca Ab L-Phenylalanine Derivatives
US8243804B2 (en) * 2005-12-01 2012-08-14 Lsi Corporation Hierarchical motion estimation for images with varying horizontal and/or vertical dimensions
CN103265495B (zh) * 2005-12-29 2016-11-16 莱西肯医药有限公司 多环氨基酸衍生物及其使用方法
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
WO2009002964A1 (en) 2007-06-26 2008-12-31 Lexicon Pharmaceuticals, Inc. Methods of treating serotonin-mediated diseases and disorders
EA201070059A1 (ru) * 2007-06-26 2010-06-30 Лексикон Фармасьютикалз, Инк. Композиции, содержащие ингибиторы триптофангидроксилазы
EP2170397A1 (en) * 2007-07-11 2010-04-07 Lexicon Pharmaceuticals, Inc. Methods and compositions for treating pulmonary hypertension and related diseases and disorders
CA2694443A1 (en) * 2007-07-26 2009-01-29 Lexicon Pharmaceuticals, Inc. Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein
EP2529740A1 (en) 2007-08-24 2012-12-05 Lexicon Pharmaceuticals, Inc. Methods of preparing 4-Phenyl-6(2,2,2-Trifluoro-1-Phenylethoxy) Pyrimidine-based compounds.
WO2009045900A2 (en) 2007-09-28 2009-04-09 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing diseases associated with low bone mass
TWI439457B (zh) 2007-09-28 2014-06-01 Lexicon Pharmaceuticals Inc （ｓ）－２－胺基－３－（４－（２－胺基－６－（（ｒ）－１－（４－氯－２－（３－甲基－１ｈ－吡唑－１－基）苯基）－２，２，２－三氟乙氧）－嘧啶－４－基）苯基）丙酸乙酯之固體形式與其使用方法
TW200932729A (en) * 2007-10-08 2009-08-01 Lexicon Pharmaceuticals Inc Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use
CA2719505A1 (en) * 2008-03-31 2009-10-08 The Trustees Of Columbia University In The City Of New York Methods of diagnosing, preventing and treating bone mass diseases
WO2010056992A1 (en) 2008-11-13 2010-05-20 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating low bone mass diseases
WO2010062829A1 (en) * 2008-11-28 2010-06-03 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for treating osteoporosis
WO2010065333A1 (en) 2008-12-01 2010-06-10 Lexicon Pharmaceuticals, Inc. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds for the treatment of osteoporosis

Also Published As

Publication number Publication date
US8759364B2 (en) 2014-06-24
CA2719505A1 (en) 2009-10-08
US20150111908A1 (en) 2015-04-23
BRPI0908719A2 (pt) 2015-08-18
KR20110008066A (ko) 2011-01-25
EP2282756A4 (en) 2012-05-02
ZA201007005B (en) 2012-02-29
WO2009123978A1 (en) 2009-10-08
CN102083454A (zh) 2011-06-01
NZ588737A (en) 2012-05-25
JP2011516486A (ja) 2011-05-26
US20110152220A1 (en) 2011-06-23
AU2009231892A1 (en) 2009-10-08
AU2009231892A8 (en) 2010-11-18
EP2282756A1 (en) 2011-02-16
EA201071146A1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
EA200870424A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
ATE494888T1 (de) Verwendung von gpr119-rezeptoragonisten zur vermehrung der knochenmasse und zur behandlung von osteoporose sowie kombinationstherapie dafür
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
PH12018500045A1 (en) Compositions and methods for treating and diagnosing asthma
ZA200906264B (en) Aminopyrimidines useful as inhibitors of protein kinases
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
MX350761B (es) Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
AR080685A1 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
MX2012001716A (es) Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
EA200970747A1 (ru) Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком
PH12013502369A1 (en) Diazacarbazoles and methods of use
EP2249838A4 (en) Pharmaceutical solid state forms
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
BR112012019902A2 (pt) "método e compostos para o crescimento muscular"
WO2010120695A3 (en) 5-ht4 receptor agonist compounds for treatment of cognitive disorders
BRPI0907220A2 (pt) métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf

Legal Events

Date Code Title Description
FA Abandonment or withdrawal